Nektar Therapeutics (NASDAQ:NKTR) Coverage Initiated at StockNews.com
StockNews.com began coverage on shares of Nektar Therapeutics (NASDAQ:NKTR – Free Report) in a research report sent to investors on Wednesday. The firm issued a hold rating on the biopharmaceutical company’s stock. A number of other equities analysts have also recently commented on the stock. William Blair reissued a “market perform” rating on shares of […]
StockNews.com began coverage on shares of Nektar Therapeutics (NASDAQ:NKTR – Free Report) in a research report sent to investors on Wednesday. The firm issued a hold rating on the biopharmaceutical company’s stock. A number of other equities analysts have also recently commented on the stock. William Blair reissued a “market perform” rating on shares of […]
